Previous 10 | Next 10 |
2023-08-24 03:43:27 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis lead product hits main goal in Phase 3 prostate cancer trial For further details...
-- Dr. Peterson’s extensive experience includes clinical development, medical affairs, and regulatory leadership in support of innovative oncology product portfolios -- Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Amy Peterson, M.D., its next Executive Vice ...
2023-08-22 09:28:26 ET More on Lilly Eli Lilly Q2: Dividends Don't Lie Eli Lilly: Q2 And 2023 Revised Guidance Impressive, But Key Is Wegovy Data Eli Lilly and Co ( LLY ) Q2 2023 Earnings Call Transcript Eli Lilly Remains A Buy With Strong Sales And Possi...
2023-08-21 07:29:59 ET More on Exelixis Exelixis: Stock Likely To Break Out Of 5-Year Inertia Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology Exelixis, Teva settle patent dispute over cancer drug Cabometyx Exelixis a new overweight...
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer – – A trend to...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-03 11:46:22 ET Summary Fitch Ratings threw a curveball at investors by downgrading its rating on U.S. federal debt for the first time since 2011 and only the second time ever. This triggered the largest one day sell-off in the NASDAQ since February and also saw volatility ...
2023-08-02 00:00:37 ET Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q2 2023 Earnings Call Aug 01, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q2 2023 Earnings Call Transcript
2023-08-01 22:20:21 ET Exelixis, Inc. (EXEL) Q2 2023 Earnings Conference Call August 01, 2023, 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Morrissey - President and Chief Executive Officer ...
2023-08-01 16:11:41 ET Exelixis press release ( NASDAQ: EXEL ): Q2 Non-GAAP EPS of $0.31 beats by $0.09 . Revenue of $469.85M (+12.0% Y/Y) beats by $25.02M . 2023 Outlook: Total revenues $1.775 billion - $1.875 billion; Net product revenues $1.575 billion -...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...